RxDoctor Payments Data

Adam Ramsey, MD

Gynecology · Willowbrook, ILNPI 1841377074

Payments from drug & device makers

What this record shows

This record is dominated by other: $5,433 of the $8,927 with a category attached, or 60.9%. KARL Storz Endoscopy-america accounts for 91.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $5,508 and has fallen 96.0% since, to $223 in 2025.

$8,927in general payments, 2019–2025

Across 51 payments — averaging $175.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • KARL Storz Endoscopy-america$8K
  • AbbVie$359
  • Bausch & Lomb Americas Inc.$150
  • Astellas Pharma US Inc$75
  • Laborie Medical Technologies Corp.$73
  • Therapeuticsmd, Inc.$55
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$6898%
  • Education$751%
  • Gifts$2,72931%
  • Other$5,43361%

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,927 in reported general payments places this provider in the 80th percentile of 68 gynecology providers in Illinois.

See all gynecology providers in Illinois

Medicare billing

Part B allowed, 2024
$504,476
Medicare patients
104
Services billed
14,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron23$10,220
Estradiol61$9,087
Estradiol (Twice Weekly)Estradiol34$5,211
ProgesteroneProgesterone, Micronized60$3,069
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst174$2,374
SynthroidLevothyroxine Sodium14$1,908
Estradiol (Once Weekly)Estradiol16$1,683
Levothyroxine Sodium92$1,029
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid85$919
Methenamine Hippurate20$825
Rosuvastatin Calcium75$769
Atorvastatin Calcium57$742
ValacyclovirValacyclovir Hcl25$673
Tinidazole17$407
Fluconazole101$406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$75$10,22023 claims
AbbVieSynthroid$359$1,90814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 68 gynecology providers in Illinois.

Other gynecology in Willowbrook

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →